{"id":"NCT00837265","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel","officialTitle":"A Randomized Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-08-21","primaryCompletion":"2009-06-26","completion":"2009-06-26","firstPosted":"2009-02-05","resultsPosted":"2023-02-03","lastUpdate":"2024-04-03"},"enrollment":334,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Chemotherapy-induced Neutropenia"],"interventions":[{"type":"BIOLOGICAL","name":"Balugrastim","otherNames":["Neugranin"]},{"type":"DRUG","name":"Pegfilgrastim","otherNames":[]},{"type":"DRUG","name":"Chemotherapy Regimen","otherNames":[]}],"arms":[{"label":"Pilot Phase: Balugrastim Low Dose","type":"EXPERIMENTAL"},{"label":"Pilot Phase: Balugrastim Medium Dose","type":"EXPERIMENTAL"},{"label":"Pilot Phase: Balugrastim High Dose","type":"EXPERIMENTAL"},{"label":"Pilot Phase: Pegfilgrastim","type":"ACTIVE_COMPARATOR"},{"label":"Main Phase: Balugrastim Medium Dose","type":"EXPERIMENTAL"},{"label":"Main Phase: Balugrastim High Dose","type":"EXPERIMENTAL"},{"label":"Main Phase: Pegfilgrastim","type":"ACTIVE_COMPARATOR"}],"summary":"Determination of the effect of balugrastim on the duration and severity of severe neutropenia.","primaryOutcome":{"measure":"Duration of Severe Neutropenia in Cycle 1","timeFrame":"Cycle 1 (cycle length = 21 days)","effectByArm":[{"arm":"Pilot Phase: Balugrastim Low Dose","deltaMin":0.9,"sd":1.37},{"arm":"Pilot Phase: Balugrastim Medium Dose","deltaMin":1.6,"sd":1.83},{"arm":"Pilot Phase: Balugrastim High Dose","deltaMin":1.1,"sd":1.48},{"arm":"Pilot Phase: Pegfilgrastim","deltaMin":0.9,"sd":1.13},{"arm":"Main Phase: Balugrastim Medium Dose","deltaMin":1,"sd":1.09},{"arm":"Main Phase: Balugrastim High Dose","deltaMin":1.3,"sd":1.22},{"arm":"Main Phase: Pegfilgrastim","deltaMin":1.2,"sd":1.34}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":10},"commonTop":["Alopecia","Neutropenia","Nausea","Asthenia","Leukopenia"]}}